No profile data available.
Guardant Health, Inc. (GH) is a healthcare company in the DNA testing equipment industry, based in Palo Alto, United States, with about 2,490 full-time employees.
It reported revenue of $982.02 million for fiscal year 2025, up 32.9% from fiscal year 2024, and net income of -$416.28 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $334.98 million, up 44.3% from a year before. United States was its largest region in fiscal year 2025, with 94% of revenue. Its market capitalization was $22.47 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Guardant Health reported $982.02 million in revenue for fiscal year 2025, up 32.9% from $739.02 million in fiscal year 2024. In Q2 2026 revenue was $334.98 million.
United States: 94% of revenue by region in fiscal year 2025, followed by International (6%).
$22.47 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (DNA testing equipment) include Natera, Inc. (NTRA), Tempus AI, Inc. (TEM), Qiagen N.v. (QGEN), Caris Life Sciences, Inc. (CAI).